Please ensure Javascript is enabled for purposes of website accessibility

Why AMAG Pharmaceuticals, Inc. and Antares Pharma, Inc. Are Soaring Today

By Brian Feroldi - Feb 15, 2018 at 12:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Favorable regulatory news causes traders to cheer.

What happened

In response to winning FDA approval for a new product, shares of AMAG Pharmaceuticals (AMAG) and Antares Pharma (ATRS) rose by double-digits in early morning trading on Thursday. Shares were up 26% and 8%, respectively, as of 11:10 a.m. EST.

So what

AMAG announced Thursday that the FDA has approved it's Makena subcutaneous auto-injector drug-device combination product. Makena is a drug used to reduce the risk of preterm birth in at-risk women. This new prefilled auto-injector is designed to make it easier for patients to inject themselves with Makena.

Antares Pharma stock is also rising on this news because the newly approved device utilizes the company's QuickShot technology. Under the terms of the agreement between these two companies, Antares will assemble the final product and then sell it back to AMAG at cost plus a markup. Antares is then eligible to receive royalties on net product sales plus milestone payments.

Given the news, it isn't hard to figure out why shares of both companies are rising.

Three medical professionals in white coats giving the thumbs up.

Image source: Getty Images.

Now what

This approval comes at an opportune time for AMAG. The company's orphan drug exclusivity for Makena expired a few weeks ago, which opens the door for generic competition. That could spell bad news for AMAG's financials since Makena represents about two-thirds of total company revenue. Management is hoping the auto-injector will help the company maintain its market share as generics start to hit pharmacy shelves.

As for Antares, this approval should allow the company's top line to continue growing at a fast rate. That increases the odds that the company will be able to eek out a small profit in 2018 as Wall Street expects.

The bottom line is that this FDA approval is a clear win for both AMAG and Antares. Investors who were bullish on either of those stocks on Wednesday have all the more reason to remain excited on Thursday.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Antares Pharma, Inc. Stock Quote
Antares Pharma, Inc.
ATRS
AMAG Pharmaceuticals, Inc. Stock Quote
AMAG Pharmaceuticals, Inc.
AMAG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.